Stupid idea ! What you need to

3
Comment
Favorite

Stupid idea ! What you need to do is to relinguish your position as CEO and let an American to take the helm.

Novo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT

UPDATE 1-Novo Nordisk open to direct New York listing, CEO Doustdar tells FTSept 23 (Reuters)-Novo NordiskNOVOb.COis open to considering a direct New York Stock Exchange listing, replacing the America

Novo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":610909850804512,"tweetId":"610909850804512","gmtCreate":1790167334341,"gmtModify":1790167853713,"author":{"id":3582873342253784,"idStr":"3582873342253784","authorId":3582873342253784,"authorIdStr":"3582873342253784","name":"WeLian","avatar":"https://community-static.tradeup.com/news/cdbf05a867d3f968294518922f7258d2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":33,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body>Stupid idea ! What you need to do is to relinguish your position as CEO and let an American to take the helm.</body></html>","htmlText":"<html><head></head><body>Stupid idea ! What you need to do is to relinguish your position as CEO and let an American to take the helm.</body></html>","text":"Stupid idea ! What you need to do is to relinguish your position as CEO and let an American to take the helm.","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/610909850804512","repostId":2669177534,"repostType":2,"repost":{"id":"2669177534","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1790151673,"share":"https://ttm.financial/m/news/2669177534?lang=en_US&edition=fundamental","pubTime":"2026-09-23 16:21","market":"us","language":"en","title":"Novo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177534","media":"Reuters","summary":"UPDATE 1-Novo Nordisk open to direct New York listing, CEO Doustdar tells FTSept 23 (Reuters)-Novo NordiskNOVOb.COis open to considering a direct New York Stock Exchange listing, replacing the America","content":"<html><head></head><body><p style=\"text-align: left;\">Novo Nordisk is open to considering a direct New York Stock Exchange listing, replacing the American depositary receipts through which US investors currently trade its shares, CEO Mike Doustdar told the Financial Times in an interview published on Wednesday.</p><p style=\"text-align: left;\">The US accounts for more than half of Novo&#39;s revenue and the bulk of sales of its diabetes and obesity drugs, but the Danish drugmaker is under pressure to regain momentum in the weight-loss market against rival Eli Lilly.</p><p style=\"text-align: left;\">&#34;I clearly do see some advantages with that,&#34; Doustdar told the newspaper when asked whether Novo would consider a direct listing on the New York Stock Exchange.</p><p style=\"text-align: left;\">&#34;Our investor community to a larger extent has shifted over the last 20 years (outside of) Scandinavia, and we are increasingly speaking to investors in the US. . . in addition to (our long-term investors),&#34; Doustdar added.</p><p style=\"text-align: left;\">Doustdar said the idea of a direct US listing had been discussed over the past decade, but there had been no &#34;active dialogue or discussions&#34; about it since he became CEO last year.</p><p style=\"text-align: left;\">&#34;I’m a type who doesn’t start with a &#39;no&#39; typically; I start with &#39;maybe. &#34;Can you give me the pros and the cons of that and let’s have a dialogue and discussions about it,&#34; Doustdar also said, though he stressed that the company is not currently exploring the idea.</p><p style=\"text-align: left;\">Novo, which is primarily listed in Copenhagen, rode a wave of demand after launching weight-loss drug Wegovy in 2021, helping it become Europe&#39;s most valuable listed firm in 2023 with a market value of more than $600 billion.</p><p style=\"text-align: left;\">Novo Nordisk didn&#39;t immediately respond to a Reuters request to comment outside regular business hours.</p><p style=\"text-align: left;\">Since then, however, Novo&#39;s shares have fallen more than 70% since its peak, while Lilly&#39;s have risen. Sales of Lilly&#39;s rival weight-loss treatment, Zepbound, are expected to exceed Wegovy sales this year by more than $7 billion, according to LSEG data.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Open to Direct New York Listing, CEO Doustdar Tells FT\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-09-23 16:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: left;\">Novo Nordisk is open to considering a direct New York Stock Exchange listing, replacing the American depositary receipts through which US investors currently trade its shares, CEO Mike Doustdar told the Financial Times in an interview published on Wednesday.</p><p style=\"text-align: left;\">The US accounts for more than half of Novo&#39;s revenue and the bulk of sales of its diabetes and obesity drugs, but the Danish drugmaker is under pressure to regain momentum in the weight-loss market against rival Eli Lilly.</p><p style=\"text-align: left;\">&#34;I clearly do see some advantages with that,&#34; Doustdar told the newspaper when asked whether Novo would consider a direct listing on the New York Stock Exchange.</p><p style=\"text-align: left;\">&#34;Our investor community to a larger extent has shifted over the last 20 years (outside of) Scandinavia, and we are increasingly speaking to investors in the US. . . in addition to (our long-term investors),&#34; Doustdar added.</p><p style=\"text-align: left;\">Doustdar said the idea of a direct US listing had been discussed over the past decade, but there had been no &#34;active dialogue or discussions&#34; about it since he became CEO last year.</p><p style=\"text-align: left;\">&#34;I’m a type who doesn’t start with a &#39;no&#39; typically; I start with &#39;maybe. &#34;Can you give me the pros and the cons of that and let’s have a dialogue and discussions about it,&#34; Doustdar also said, though he stressed that the company is not currently exploring the idea.</p><p style=\"text-align: left;\">Novo, which is primarily listed in Copenhagen, rode a wave of demand after launching weight-loss drug Wegovy in 2021, helping it become Europe&#39;s most valuable listed firm in 2023 with a market value of more than $600 billion.</p><p style=\"text-align: left;\">Novo Nordisk didn&#39;t immediately respond to a Reuters request to comment outside regular business hours.</p><p style=\"text-align: left;\">Since then, however, Novo&#39;s shares have fallen more than 70% since its peak, while Lilly&#39;s have risen. Sales of Lilly&#39;s rival weight-loss treatment, Zepbound, are expected to exceed Wegovy sales this year by more than $7 billion, according to LSEG data.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","NVOX":"2倍做多NVO ETF-Defiance","NVO":"诺和诺德","MEDX":"HORIZON KINETICS MEDICAL ETF","LU2168564065.EUR":"AZ ALLOCATION - TREND \"AAZ\" (EUR) ACC","GDOC":"Goldman Sachs Future Health Care Equity ETF","CURE":"Direxion Daily Healthcare Bull 3X ETF","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","FHLC":"Fidelity MSCI Health Care Index","ILDR":"First Trust Innovation Leaders ETF","MHIP":"Milliman Healthcare Inflation Plus ETF","LLYZ":"2倍做空LLY ETF-Defiance","LU0133085943.USD":"T ROWE PRICE US BLUE CHIP EQUITY \"A\" ACC","PPH":"VanEck Pharmaceutical ETF","AGNG":"Global X Aging Population ETF","TMED":"T. Rowe Price Health Care ETF","IXJ":"全球医疗业ETF-iShares","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","HRTS":"Tema Heart & Health ETF","PJP":"INVESCO PHARMACEUTICALS ETF","MEDI":"HARBOR HEALTH CARE ETF","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","VHT":"Vanguard Health Care ETF","RXL":"ProShares Ultra Health Care","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","CANC":"TEMA ONCOLOGY ETF","IYH":"iShares U.S. Healthcare ETF","IHE":"iShares U.S. Pharmaceuticals ETF","WDNA":"WisdomTree BioRevolution Fund","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","BK4534":"瑞士信贷持仓","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","TRUH":"VanEck Healthcare TruSector ETF","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","OZEM":"Roundhill GLP-1 & Weight Loss ETF","XLV":"健康照护类股ETF-SPDR","NVOC":"Corgi NVO 2x Daily ETF","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","NVOH":"Novo Nordisk A/S B Shares ADRhedged"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL6N45F05A:2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2669177534","content_text":"Novo Nordisk is open to considering a direct New York Stock Exchange listing, replacing the American depositary receipts through which US investors currently trade its shares, CEO Mike Doustdar told the Financial Times in an interview published on Wednesday.The US accounts for more than half of Novo's revenue and the bulk of sales of its diabetes and obesity drugs, but the Danish drugmaker is under pressure to regain momentum in the weight-loss market against rival Eli Lilly.\"I clearly do see some advantages with that,\" Doustdar told the newspaper when asked whether Novo would consider a direct listing on the New York Stock Exchange.\"Our investor community to a larger extent has shifted over the last 20 years (outside of) Scandinavia, and we are increasingly speaking to investors in the US. . . in addition to (our long-term investors),\" Doustdar added.Doustdar said the idea of a direct US listing had been discussed over the past decade, but there had been no \"active dialogue or discussions\" about it since he became CEO last year.\"I’m a type who doesn’t start with a 'no' typically; I start with 'maybe. \"Can you give me the pros and the cons of that and let’s have a dialogue and discussions about it,\" Doustdar also said, though he stressed that the company is not currently exploring the idea.Novo, which is primarily listed in Copenhagen, rode a wave of demand after launching weight-loss drug Wegovy in 2021, helping it become Europe's most valuable listed firm in 2023 with a market value of more than $600 billion.Novo Nordisk didn't immediately respond to a Reuters request to comment outside regular business hours.Since then, however, Novo's shares have fallen more than 70% since its peak, while Lilly's have risen. Sales of Lilly's rival weight-loss treatment, Zepbound, are expected to exceed Wegovy sales this year by more than $7 billion, according to LSEG data.","news_type":1,"symbols_score_info":{"PJP":0.6,"RXL":0.6,"TRUH":0.6,"XLV":0.6,"IXJ":0.6,"NVOH":0.6,"IHE":0.6,"PPH":0.6,"NVOX":0.6,"WDNA":0.6,"AGNG":0.6,"HRTS":0.6,"LLYZ":0.6,"TMED":0.6,"MEDI":0.6,"THNR":0.6,"GDOC":0.6,"FTXH":0.6,"NVO":2,"NVOC":0.6,"FHLC":0.6,"ILDR":0.6,"MHIP":0.6,"CANC":0.6,"CURE":0.6,"OZEM":0.6,"VHT":0.6,"IYH":0.6,"JDOC":0.6,"MEDX":0.6}},"isVote":1,"tweetType":1,"viewCount":218,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":87,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}